Corvus Pharmaceuticals, Inc. Employee Benefits and Share-based Compensation
Corvus Pharmaceuticals, Inc. (CRVS) reported Employee Benefits and Share-based Compensation of $1.25 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2025-11-04
- Corvus Pharmaceuticals, Inc. employee benefits and share-based compensation for the quarter ending 2025-09-30 was $1.25M, a 70.16% increase year-over-year.
- Corvus Pharmaceuticals, Inc. employee benefits and share-based compensation for the quarter ending 2025-06-30 was $1.26M, a 63.33% increase year-over-year.
- Corvus Pharmaceuticals, Inc. employee benefits and share-based compensation for the quarter ending 2025-03-31 was $1.25M, a 81.57% increase year-over-year.
- Corvus Pharmaceuticals, Inc. employee benefits and share-based compensation for the quarter ending 2024-09-30 was $734.00K.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month |
|---|---|---|---|
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-04 | $2.50M derived: sum of 2 quarters · filed 2025-11-04 | $3.76M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.26M 10-Q · filed 2025-08-07 | $2.51M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.25M 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | $734.00K 10-Q · filed 2025-11-04 | $1.50M derived: sum of 2 quarters · filed 2025-11-04 | $2.19M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $769.00K 10-Q · filed 2025-08-07 | $1.46M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $689.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |